Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Intec Pharma Crashes as Phase III Parkinson’s Treatment Fails in Comparison Trial

Shares of Israel-based Intec Pharma Ltd. were down nearly 82 percent after the company announced that the Phase III Parkinson’s disease therapy Accordion Pill failed to demonstrate statistical superiority to treatment with Sinemet, a combination of carbidopa and levodopa.

Read More »

Centogene Launches Two Year Global Parkinson’s Disease Study

Centogene announced the initiation of a 24-month global study to investigate the genetic factors in Parkinson’s disease.

Read More »

Lundbeck to acquire Abide Therapeutics

The acquisition of Abide Therapeutics Inc. will provide H. Lundbeck A/S with a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s syndrome.

Read More »

Pfizer buys stake in French gene therapy firm Vivet

Pfizer acquired a 15 percent stake in Vivet Therapeutics as well as an exclusive option to fully acquire the business, a deal that will give the New York-based pharma giant access to the French company’s experimental gene therapy for a rare genetic disorder.

Read More »

A Link Between Gum Disease and Alzheimer’s?

Researchers with Cortexyme published research in the journal Science Advances describing the role of Porphyromonas gingivalis, a bacteria that causes gingivitis, to Alzheimer’s disease.

Read More »

A Blood Test That Can ID Alzheimer’s Risk Up To 16 Years Before Symptoms

Scientists at DZNE, HIH, and the University Hospital Tuebingen identified a protein in blood that can precisely track Alzheimer’s disease progression before the first symptoms appear.

Read More »

Japan scientists to use ‘reprogrammed’ stem cells to fight Parkinson’s

Japanese scientists said they will start clinical trials in August 2018 on a treatment for Parkinson’s disease, transplanting “reprogrammed” stem cells into brains, seeking a breakthrough in treating the neurodegenerative disorder.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom